| |
Significant patient populations, top clinical institutions, and ease of
regulatory compliance combined to support oncology trial success in APAC. Download our white paper to explore the growth of oncology trials in APAC countries and strategies to support global study success in this dynamic and complex region. Premier Research. Built for Biotech℠
|
|
Today's Big NewsOct 21, 2022 |
|
Sino Biological offers rapid mouse monoclonal antibody development service on the Beacon®️ platform and obtains positive clones within 35 days, which accelerates the process of antibody (drug) discovery. Learn more.
|
|
| By Nick Paul Taylor With Halloween around the corner, the bogeyman of biotech—high placebo rate—has spooked investors in Immunic, sending its stock down 71% to $2.60 in premarket trading. The company blamed the response rate in the placebo arm for a disappointing look at interim, blinded data from its phase 1b psoriasis trial. |
|
|
|
By James Waldron Whisper it, but biotech SPACs appear to be back in fashion. The latest is cancer-focused Aum Biosciences, which is merging with blank check company Mountain Crest Acquisition to put its MNK and TRK inhibitors into phase 2 testing. |
Sponsored by Cullinan Oncology Cullinan Oncology’s strategic approach to research and development, focusing on modality-agnostic target oncology, positions the company to thrive. |
Sponsored by PathAI TME research is recognized as one of the most promising areas in oncology drug development. AI-powered digital pathology reveals new insights previously hidden by laborious manual pathology methods. |
By Nick Paul Taylor Ten months after revealing a phase 3 flop, Summit Therapeutics has shared data from the antibiotic trial and framed it as evidence of a potential need to change how anti-infectives are developed and assessed. |
By Gabrielle Masson In a move to become a “pure play” RNA company, Altamira Therapeutics is selling off 90% of its Zilentin subsidiary and its inner ear R&D work for the chance to make up to $55 million in biobucks. |
By Gabrielle Masson Gilead’s Kite Pharma has tied down a licensing deal for Refuge Biotechnologies’ gene expression platform in hopes of developing new blood cancer treatments, potentially setting flight to a new generation of CAR-Ts. |
By Fraiser Kansteiner Scynexis has laid out a strategy to “refocus its resources” on the clinical development of its antifungal ibrexafungerp in “hospital-based indications in which higher long-term returns are expected.” In turn, the company will license out the drug in its approved indication and terminate its entire commercial team. |
By Conor Hale Known as conduction system pacing, the approach involves connecting the implant’s leads directly to the bundles of intertwined cells that help govern the repeated contractions of the cardiac muscle. |
By Paul Burton,Sharon Ray As partners in a venture capital firm dedicated to accelerating inclusive innovation, we believe now is the time to double down on supporting health startups led by diverse founders who have innovative ideas to close gaps in care. |
By Teresa Carey This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more. |
By Gabrielle Masson,Max Bayer A new merger deal has Advaxis and Ayala joining forces, though not everyone from Ayala’s team will be coming with. |
By Angus Liu J&J and Legend Biotech's multiple myeloma CAR-T has ramped up sales early in its launch. Sanofi is selling a plant responsible for delivering all the company's products in Japan. J&J has offloaded a plant in India that it never opened. South Korea’s LG Chem reached a $566 million deal to acquire Aveo Oncology. And more. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about our special report on the top 10 vaccine company rankings. We also report the news on Pfizer's kickback lawsuit, OTC hearing aids and more. |
|
|---|
|
|
|
Wednesday, October 26, 2022 | 1pm ET / 10am PT In this webinar, we’ll explore how incorporating telehealth genetic screening into clinical trials can accelerate patient identification, recruitment and engagement. Register now.
|
|
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| ResearchLearn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
